Rabbit Recombinant Monoclonal IMPA1 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Mouse, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | Flow Cyt (Intra) | |
---|---|---|
Human | Tested | Tested |
Mouse | Tested | Expected |
Rat | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/10000 - 1/100000 | Notes - |
Species Human | Dilution info 1/10000 - 1/100000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/300 | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Select an associated product type
Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Has broad substrate specificity and can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose 1-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates.
IMPA, IMPA1, Inositol monophosphatase 1, IMP 1, IMPase 1, D-galactose 1-phosphate phosphatase, Inositol-1(or 4)-monophosphatase 1, Lithium-sensitive myo-inositol monophosphatase A1
Rabbit Recombinant Monoclonal IMPA1 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Mouse, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The inositol monophosphatase 1 (IMPA1) also known by its alternative names Inositol-1(or 4)-monophosphatase and IMPase 1 is an enzyme that dephosphorylates inositol monophosphate to produce free inositol. IMPA1 has a molecular mass of approximately 29 kDa. Expression of IMPA1 occurs broadly in mammalian tissues with high levels in brain and kidney. The enzyme requires magnesium ions for its activity and operates efficiently under low lithium concentration.
The enzyme holds importance for phosphatidylinositol signaling and plays an important role in cellular inositol recycling. IMPA1 functions as part of a monomer or dimer but does not require complex formation with other proteins to operate effectively. Its enzyme activity maintains intracellular inositol levels which is important for cell membrane phospholipid integrity and secondary messenger systems.
IMPA1 is integral to the phosphoinositide signaling pathway contributing to the regeneration of inositol triphosphate (IP3) and aiding in cell signal transduction processes. It also participates in the synthesis of myo-inositol by catalyzing the final step of inositol phosphate metabolism. Within these pathways it works closely with proteins like inositol polyphosphate 1-phosphatase (INPP1) and inositol polyphosphate 5-phosphatase (INPP5).
IMPA1 has associations with bipolar disorder and schizophrenia. Lithium a common medication for bipolar disorder inhibits IMPA1 activity which affects inositol signaling. The enzyme's function and regulation impact synaptic transmission and neurochemical signaling with connections to proteins like glycogen synthase kinase 3 beta (GSK3B) in these disorders. Understanding of IMPA1's role provides insights into its potential therapeutic targets for mood disorders and other neuropsychiatric conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Intracellular flow cytometric analysis of PC3 cells labeling IMPA1 using ab191570at 1/300 dilution (red), Isotype control (green). Secondary antibody was Goat anti rabbit IgG (FITC) at 1/150 dilution. Cells were fixed in 2% paraformaldehyde prior to staining.
5% NFDM/TBST blocking buffer
All lanes: Western blot - Anti-IMPA1 antibody [EPR15405] (ab191570) at 1/20000 dilution
All lanes: Mouse brain tissue lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 30 kDa
5% NFDM/TBST blocking buffer
All lanes: Western blot - Anti-IMPA1 antibody [EPR15405] (ab191570) at 1/20000 dilution
Lane 1: Jurkat cell lysate at 20 µg
Lane 2: PC3 cell lysate at 20 µg
Lane 3: HCT 116 cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 30 kDa
5% NFDM/TBST blocking buffer
All lanes: Western blot - Anti-IMPA1 antibody [EPR15405] (ab191570) at 1/100000 dilution
All lanes: Human testis lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 30 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com